Drugs / Vitamin D Supplement
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00670501 Background | Aug 1996 → Apr 1999 | postmenopausal osteoporosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT06204796 Comparator | Aug → Sep 2023 | lichen planus, oral, vitamin D deficiency | Fayoum University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vitamin D Supplement | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00670501 ↗ |
| Route | Oral | “Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement” NCT00670501 ↗ |